Bristol-Myers Squibb is warning against the use of the antibiotic drug Tequin in diabetic patients after reports of several fatalities, the U.S. Food and Drug Administration said recently.
According to the FDA, the company is adding a contraindication warning for diabetics to the drug’s label as well as strengthening its warning that Tequin can cause both low and high blood sugar levels in patients. The label will include warnings that patients who are older, have renal insufficiency and take other medicine that affects glucose levels can also be at risk, according to the agency.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.